Glaxo keeps Ebola vax manufacturing in-house; 'Anti-typhoid' gene could improve vaccines;

> GlaxoSmithKline ($GSK) is keeping its Ebola vaccine production in-house. Report

> Scientists have found a gene variant that may provide better protection against typhoid fever. Report

> VaxInnate's quadrivalent seasonal influenza vaccine candidate has met its Phase I endpoints. Release

> Malaysian biotech Sentinext Therapeutics has successfully completed a $14 million Series B financing round that will take its hand, foot and mouth disease vaccine into Phase I clinical trials. More

> Abivax has inked a pact with the Finlay Institute to commercialize meningococcal and typhoid vaccines in Asia and Latin America. Release

> Malaria vaccine maker SutroVax is in search of Series A funding. More

And Finally... Unused flu vaccine costs California $1 million each year. More

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.